SELECT LANGUAGE BELOW

Wells Fargo predicts a market ‘short squeeze’ is approaching. Here are the stocks to consider for trading.

Wells Fargo predicts a market 'short squeeze' is approaching. Here are the stocks to consider for trading.

Wells Fargo Sees Positive Outlook for Stocks

Wells Fargo is anticipating several factors that could drive stock prices up, particularly focusing on heavily shorted stocks that have been lagging. Analysts on Wall Street suggest that market dynamics, including a “reflation” and a potential short squeeze, are being influenced by increased consumer spending due to tax refunds—averaging around $800 per person—along with quicker profit growth in struggling sectors and more liquidity from the Federal Reserve.

In a note released on Tuesday, Wells Fargo analysts, led by Oh Sung Kwon, highlighted a number of heavily shorted and underperforming stocks within the Russell 3000 index that might be poised for recovery. Among these are stocks that Wells Fargo rates as Overweight, such as Herc Holdings. Equipment rental suppliers, for instance, have seen a decline of 15% in the past year.

Recently, KeyBanc Capital Markets upgraded Haak’s rating from sector weight to overweight, with analyst Ken Newman setting a price target of $200, which indicates a potential upside of 27%. Newman mentioned, “We think the initial integration challenges post-HEES agreement have been addressed, and we anticipate that achieving up to $125 million in targeted cost synergies by the end of the second year could boost our outlook.” This refers to the acquisition of H&E Equipment Services. He also noted that the stabilization of the operating force after the transaction allowed the company to concentrate on these cost efficiencies.

KeyBanc further suggested that the recent completion of IT system integration with the acquired fleet could act as an additional catalyst for improved efficiency.

Another stock highlighted by Wells Fargo is Vera Therapeutics, a biotech company that has experienced an 11% increase over the past year. Bank of America began covering Vera in October, issuing a buy rating with a target price of $48. Analyst Dina Ramadan expressed optimism, stating, “We expect VERA stock to appreciate with the launch of the flagship drug atacicept into a lucrative market, which could address competitive concerns.”

Other companies on Wells Fargo’s radar include energy firm Matador Resources and industrial manufacturer Ingersoll Rand.

Facebook
Twitter
LinkedIn
Reddit
Telegram
WhatsApp

Related News